159 related articles for article (PubMed ID: 27767099)
1. Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany.
Rüschoff J; Lebeau A; Kreipe H; Sinn P; Gerharz CD; Koch W; Morris S; Ammann J; Untch M;
Mod Pathol; 2017 Feb; 30(2):217-226. PubMed ID: 27767099
[TBL] [Abstract][Full Text] [Related]
2. HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany.
Baretton G; Kreipe HH; Schirmacher P; Gaiser T; Hofheinz R; Berghäuser KH; Koch W; Künzel C; Morris S; Rüschoff J;
Virchows Arch; 2019 May; 474(5):551-560. PubMed ID: 30826877
[TBL] [Abstract][Full Text] [Related]
3. Statistical modelling of HER2-positivity in breast cancer: Final analyses from two large, multicentre, non-interventional studies in Germany.
Rüschoff J; Lebeau A; Sinn P; Schildhaus HU; Decker T; Ammann J; Künzel C; Koch W; Untch M
Breast; 2020 Feb; 49():246-253. PubMed ID: 31918324
[TBL] [Abstract][Full Text] [Related]
4. Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands.
van Dooijeweert C; Deckers IAG; Baas IO; van der Wall E; van Diest PJ
Breast Cancer Res Treat; 2019 Jun; 175(2):487-497. PubMed ID: 30825048
[TBL] [Abstract][Full Text] [Related]
5. Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing?
Rakha EA; Pigera M; Shin SJ; D'Alfonso T; Ellis IO; Lee AH
Histopathology; 2016 Jul; 69(1):20-4. PubMed ID: 26542743
[TBL] [Abstract][Full Text] [Related]
6. Quality assessment of HER2 testing by monitoring of positivity rates.
Choritz H; Büsche G; Kreipe H;
Virchows Arch; 2011 Sep; 459(3):283-9. PubMed ID: 21809092
[TBL] [Abstract][Full Text] [Related]
7. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
[TBL] [Abstract][Full Text] [Related]
8. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer.
Kaufman PA; Bloom KJ; Burris H; Gralow JR; Mayer M; Pegram M; Rugo HS; Swain SM; Yardley DA; Chau M; Lalla D; Yoo B; Brammer MG; Vogel CL
Cancer; 2014 Sep; 120(17):2657-64. PubMed ID: 24930388
[TBL] [Abstract][Full Text] [Related]
9. HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable.
Beltjens F; Bertaut A; Pigeonnat S; Loustalot C; Desmoulins I; Charon-Barra C; Coudert B; Fumoleau P; Arveux P; Arnould L
Eur J Cancer Care (Engl); 2017 Mar; 26(2):. PubMed ID: 26503126
[TBL] [Abstract][Full Text] [Related]
10. Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization.
Vogel UF
Diagn Pathol; 2010 Jul; 5():50. PubMed ID: 20670419
[TBL] [Abstract][Full Text] [Related]
11. Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients From 19 Chinese Representative Clinical Centers.
Shui R; Liang X; Li X; Liu Y; Li H; Xu E; Zhang Z; Lian Y; Guo S; Yao M; Yang H; Xu F; Liu Y; Liu J; Guo D; Wang K; Li J; Ma Y; Wang J; Shi J; Bu H; Yang W
Clin Breast Cancer; 2020 Feb; 20(1):e65-e74. PubMed ID: 31669267
[TBL] [Abstract][Full Text] [Related]
12. Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.
Yardley DA; Kaufman PA; Huang W; Krekow L; Savin M; Lawler WE; Zrada S; Starr A; Einhorn H; Schwartzberg LS; Adams JW; Lie Y; Paquet AC; Sperinde J; Haddad M; Anderson S; Brigino M; Pesano R; Bates MP; Weidler J; Bosserman L
Breast Cancer Res; 2015 Mar; 17(1):41. PubMed ID: 25886996
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
[TBL] [Abstract][Full Text] [Related]
14. Comparison of breast cancer in Indonesia and Malaysia--a clinico-pathological study between Dharmais Cancer Centre Jakarta and University Malaya Medical Centre, Kuala Lumpur.
Ng CH; Pathy NB; Taib NA; Teh YC; Mun KS; Amiruddin A; Evlina S; Rhodes A; Yip CH
Asian Pac J Cancer Prev; 2011; 12(11):2943-6. PubMed ID: 22393968
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.
Fan Y; Ding X; Xu B; Ma F; Yuan P; Wang J; Zhang P; Li Q; Luo Y
Medicine (Baltimore); 2015 Nov; 94(46):e2066. PubMed ID: 26579819
[TBL] [Abstract][Full Text] [Related]
16. Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study.
Varga Z; Noske A; Ramach C; Padberg B; Moch H
BMC Cancer; 2013 Dec; 13():615. PubMed ID: 24377754
[TBL] [Abstract][Full Text] [Related]
17. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
Varga Z; Noske A
PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
[TBL] [Abstract][Full Text] [Related]
18. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
[TBL] [Abstract][Full Text] [Related]
19. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
